Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic MSC Therapy in Chronic Kidney Disease
NCT04869761Phase 1Completed
- Start
- Oct 2021
- Primary completion
- Apr 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CSCC_ASC in chronic kidney disease (CKD) and diabetic nephropathy (DN) (2 arms). Primary endpoint: Adverse events and/or serious adverse events at 22 months. Started Oct 2021; status: completed.
02
Drugs
CSCC_ASC
03
Conditions
chronic kidney disease (CKD)diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT04869761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04869761.